Navigation Links
Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
Date:3/28/2011

or have failed, two or more currently approved tyrosine kinase inhibitors.(iii)

Conduct of the ChemGenex Group's business in the ordinary courseDuring the Condition Period, no member of the ChemGenex Group conducts its business otherwise than in the ordinary course.(iv)

Instances of conduct not in the ordinary courseWithout limiting paragraph (iii), during the Condition Period, no member of the ChemGenex Group:  (A)

acquires any one or more entities, businesses or assets (or any interest in any one or more entities, businesses or assets) the price, or aggregate price, of which exceeds $1.0 million; (B)

disposes any one or more entities, businesses or assets (or any interest in any one or more entities, businesses or assets) the price, or aggregate price, of which exceeds $1.0 million;  (C)

enters into any agreement involving a commitment greater than $1.0 million or the term of which cannot be terminated within 6 months; (D)

incurs or commits to, or grants to another person a right the exercise of which would involve incurring or committing to, any capital expenditure in respect of any one or more items which, or the aggregate amount of which, exceeds $1.0 million;(E)

incurs any indebtedness or issues any debt securities other than:(aa)

to another member of the ChemGenex Group; or(bb)

trade credit in the ordinary course of business;(F)

releases or materially varies any obligation owing to it by any person which by reason of its quantum or its nature is material to the ChemGenex Group taken as a whole;(G)

enters into any joint venture, shareholders, partnership or strategic alliance agreement;(H)

gives a financial benefit to any related party of ChemGenex with the meaning of Chapter 2E of the Corporations Act;(I)

employs or appoints any director or employee in respect of which the total annual employment or appointment costs of that person would exceed
'/>"/>

SOURCE Cephalon, Inc.; ChemGenex Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Cephalon Announces Definitive Agreement to Acquire Gemin X
3. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
4. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
5. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
6. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
7. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
8. Cephalon to Webcast Investor Day
9. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
10. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
11. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 1, 2011 Serina Therapeutics, Inc. President and CEO Randall ... a $9.5 million financing round to advance its lead oncology ... early 2012. "We are pleased to report to ... round that was launched in late 2010. This is a ...
... 2011 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... officer will present a corporate overview at the Goldman Sachs ... p.m. PT.  The conference will be held at the Terranea ... webcast and audio archive of the presentation will be available ...
Cached Medicine Technology:Serina Therapeutics, Inc. Closes $9.5 Million Financing Round 2
(Date:4/23/2014)... Washington, April 21, 2014 Five for-profit and ... of $1.25 million in Proof of Concept grants ... ideas into commercial products, the Life Sciences Discovery ... $300,000 Entrepreneur Mentoring Program grant to the Washington ... statewide advisory network to train the next generation ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/22/2014)... school sport in the United States with 1 million ... the Center for Injury Research and Policy at Nationwide ... the occurrence and distribution patterns of basketball-related injuries treated ... setting among adolescents and teens. , The study, published ... examined data relating to adolescents 13-19 years of age ...
(Date:4/22/2014)... care for low-income patients may ease the financial ... improving patient health, researchers have concluded. , A ... that avoid costs associated with insurance administration can ... rates and emergency room visits, according to Mark ... , The researchers estimated that the major hospital ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... unlikely to be caused by a decrease in mammography screening, ... Journal of the National Cancer Institute . It is ... , There has been a recent, rapid decline in ... Initiative study found that hormone therapy was associated with an ...
... B: apo A-I ratio is not a better predictor ... that include total cholesterol and HDL-C, according to a ... Current risk-prediction instruments and guidelines for coronary heart disease ... (LDL-C), total cholesterol, or both for CHD risk assessment. ...
... can diagnose venous thromboembolic disease (VTED) in cancer patients ... the thorax, abdomen, and pelvis which are regularly done ... according to a recent study conducted by radiologists at ... , Venous thromboembolic disease can be fatal if left ...
... warfarin) and antiplatelet drugs (e.g., acetylsalicylic acid) are ... diseases. In this study, Joseph Delaney MSc, Dr. ... in 4,028 cases with a diagnosis of gastrointestinal ... Kingdom. They documented a 46-fold increase in the ...
... Spirometry testing is a widely accepted and encouraged ... new research shows that it is not used nearly ... CHEST, the peer-reviewed journal of the American College of ... patients with a COPD diagnosis ever received spirometry testing. ...
... in a nursing home or take medication to lower ... following hospitalization for heatstroke, according to a study posted ... issue of Archives of Internal Medicine, one of the ... online today found that being confined to bed, not ...
Cached Medicine News:Health News:Drop in breast cancer incidence linked to hormone use, not mammograms 2Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Study says COPD testing is not measuring up 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 3
... Long Instrument for applications in ... Plus Long Instrument with 150mm ... endoscopic entry device that has ... is used to establish entry ...
... The Autosuture™ Blunt Tip Trocar consists ... handle and a valve body assembly. , ... internal flapper valve and seal to prevent ... withdrawn. The Autosuture™ Blunt Tip Trocar includes ...
... components are supplied sterile. , ,The Step™ ... sterile in 2/3, 5, 7/8, 10 and 12 ... They are used in conjunction with the Step™ ... Expandable Sleeve. The 5, 7/8, 10 and 12 ...
... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
Medicine Products: